See more : Turbodyne Technologies, Inc. (TRBD) Income Statement Analysis – Financial Results
Complete financial analysis of Elevai Labs, Inc. Common Stock (ELAB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Elevai Labs, Inc. Common Stock, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- National CineMedia, Inc. (NCMI) Income Statement Analysis – Financial Results
- Valiant Holding AG (0QPU.L) Income Statement Analysis – Financial Results
- Magna International Inc. (MGA) Income Statement Analysis – Financial Results
- MIRA Pharmaceuticals, Inc. (MIRA) Income Statement Analysis – Financial Results
- Nilachal Refractories Limited (NILACHAL.BO) Income Statement Analysis – Financial Results
Elevai Labs, Inc. Common Stock (ELAB)
Industry: Biotechnology
Sector: Healthcare
About Elevai Labs, Inc. Common Stock
Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 1.71M | 766.28K | 827.00 | 0.00 |
| Cost of Revenue | 578.02K | 324.00K | 2.85K | 0.00 |
| Gross Profit | 1.13M | 442.28K | -2.02K | 0.00 |
| Gross Profit Ratio | 66.25% | 57.72% | -244.01% | 0.00% |
| Research & Development | 426.24K | 228.75K | 123.63K | 118.86K |
| General & Administrative | 3.37M | 1.54M | 602.73K | 95.94K |
| Selling & Marketing | 660.29K | 192.86K | 31.61K | 6.08K |
| SG&A | 4.03M | 1.80M | 633.96K | 102.99K |
| Other Expenses | -3.32M | -198.44K | -25.45K | 0.00 |
| Operating Expenses | 1.13M | 2.23M | 783.04K | 222.91K |
| Cost & Expenses | 5.47M | 2.55M | 785.89K | 222.91K |
| Interest Income | 5.56K | 7.70K | 0.00 | 0.00 |
| Interest Expense | 19.53K | 2.63K | 0.00 | 0.00 |
| Depreciation & Amortization | 11.65K | 6.51K | 2.76K | 221.84K |
| EBITDA | -4.27M | -1.78M | -782.30K | -1.07K |
| EBITDA Ratio | -249.35% | -232.52% | -94,594.92% | 0.00% |
| Operating Income | -3.67M | -1.79M | -785.06K | -221.84K |
| Operating Income Ratio | -214.24% | -233.37% | -94,928.66% | 0.00% |
| Total Other Income/Expenses | -632.45K | -11.98K | 321.00 | -1.07K |
| Income Before Tax | -4.30M | -1.80M | -784.74K | -222.91K |
| Income Before Tax Ratio | -251.17% | -234.94% | -94,889.84% | 0.00% |
| Income Tax Expense | 0.00 | -2.00 | 3.00 | -1.07K |
| Net Income | -4.30M | -1.80M | -784.74K | -222.91K |
| Net Income Ratio | -251.17% | -234.94% | -94,889.84% | 0.00% |
| EPS | -0.40 | -0.19 | -0.05 | -0.05 |
| EPS Diluted | -0.40 | -0.19 | -0.05 | -0.05 |
| Weighted Avg Shares Out | 10.75M | 9.53M | 17.33M | 4.41M |
| Weighted Avg Shares Out (Dil) | 10.75M | 9.53M | 17.33M | 4.41M |
Elevai Labs Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
NEWPORT BEACH, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, today reported financial results for the second quarter ended June 30, 2024 and provided a business...
Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD
Professor of Medicine at the University of California, Los Angeles (UCLA), where he serves as Director of the UCLA Metabolism Research Theme. Over 180 publications in the field of obesity & metabolism, along with multiple NIH-funded projects as Principal Investigator.
Top 4 Risk Off Stocks You'll Regret Missing In July
The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies. `
Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs
NEWPORT BEACH, Calif., June 14, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, announced the formation of a new Scientific Advisory Board to support the advancement of EL-22, a...
Elevai Labs Inc Subsidiary, Elevai Biosciences, to Present at the UCLA LA-BEST 2024 Conference
NEWPORT BEACH, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, announced that Chief Executive Officer Dr. Jordan R.
Elevai Labs Inc. Reports First Quarter 2024 Financial Results
NEWPORT BEACH, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, today reported financial results for the first quarter ended March 31, 2024.
Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity
Preclinical results of EL-22 from a 2022 study demonstrated physiological (serum creatine kinase level), physical (body weight change), and functional (rotarod test) improvements in the dystrophic features of mdx mice, a mouse model of Duchenne muscular dystrophy (DMD)1. Elevai believes...
Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare
Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
Elevai Labs Highlights Global Distribution Partnership Overview: Contracts May Secure $4.9M Top Line Revenue Commitments
Five international distribution agreements signed to date Cumulative contracted minimum purchase requirements of $4.9M in the first five years Up to five additional international distribution agreements in discussion NEWPORT BEACH, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- ELEVAI Labs Inc. (NASDAQ: ELAB) (“Elevai” or...
Source: https://incomestatements.info
Category: Stock Reports